nirmatrelvir/ritonavir

Overview

Nirmatrelvir/ritonavir (brand name Paxlovid) is an oral antiviral combination therapy developed for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults at high risk of progression to severe disease. The formulation pairs two distinct agents with complementary pharmacological roles. Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro, also designated non-structural protein 5 or nsp5), a cysteine protease that is essential for processing viral polyproteins into functional replicase components; inhibition of this enzyme blocks viral replication at an early, critical step. The drug forms an extensive hydrogen bond network with residues in the Mpro active site, including interactions with the catalytic dyad comprising a cysteine and a histidine residue, a binding mode that distinguishes it mechanistically from newer non-peptidomimetic scaffolds. Ritonavir, originally developed as an HIV-1 protease inhibitor, serves as a pharmacokinetic booster in this combination: at sub-therapeutic antiviral doses it inhibits cytochrome P450 3A4 (CYP3A4), thereby slowing nirmatrelvir's hepatic metabolism and maintaining plasma concentrations sufficient for antiviral efficacy. The standard adult dosage evaluated in clinical and real-world contexts is 300 mg nirmatrelvir/100 mg ritonavir twice daily for five days.

Beyond its primary indication, ritonavir has attracted independent investigational interest. In HIV medicine it was one of the earliest protease inhibitors, and more recent work has explored whether it or structurally related agents (such as lopinavir) might inhibit parasite or cancer-relevant enzymes. These secondary investigations highlight the broader pharmacological versatility of the HIV protease inhibitor class, even though ritonavir itself was shown in at least one study to lack activity against certain cancer-cell targets, distinguishing its mechanism from those of other protease inhibitors.

Focus of Latest Publications

Recent publications on nirmatrelvir/ritonavir have focused on both its established role as a SARS-CoV-2 main protease inhibitor and on real-world and special-population use. Several studies used nirmatrelvir/ritonavir as a reference comparator in drug discovery work targeting the viral main protease, including virtual screening and structure-based design efforts aimed at identifying alternative scaffolds with improved safety or potency. In these studies, nirmatrelvir was used to benchmark binding affinity or enzymatic inhibition against newly proposed compounds, such as spiropyrrolidinoxindole hits, thiazole-based peptidomimetics, and curcumin-derived carbon nanomaterials.

Experimental and computational studies also compared candidate inhibitors directly with nirmatrelvir at the SARS-CoV-2 main protease. One computational analysis of curcumin-based nanomaterials reported higher predicted binding affinities for the carbon dots than for nirmatrelvir, with molecular dynamics and MM-PBSA analyses supporting stable complexes. Another study of thiazole-based peptidomimetic inhibitors found that one compound, AD06, had Mpro inhibitory potency comparable to nirmatrelvir, while another compound, AD05, showed stronger antiviral activity in cells despite weaker enzymatic inhibition. Additional structure-based work identified nonpeptidomimetic 3CLpro hits and nicotine-inspired covalent inhibitors, placing nirmatrelvir in the context of ongoing efforts to develop alternative chemotypes against the same viral target.

Beyond discovery studies, recent publications have examined nirmatrelvir/ritonavir in clinical and pharmacokinetic settings. A phase 1 study in healthy lactating women found that both nirmatrelvir and ritonavir were present in breast milk at concentrations lower than maternal plasma after multiple doses, with estimated infant exposure remaining low and all adverse events mild to moderate. The regimen was reported to be safe and well tolerated in this population. A real-world study from the Kingdom of Saudi Arabia described the demographic and clinical characteristics, treatment patterns, and healthcare resource use among adults with COVID-19 receiving nirmatrelvir/ritonavir, reflecting interest in how the therapy is used in routine practice.

Observational effectiveness research has also evaluated methodological issues in estimating the benefit of nirmatrelvir/ritonavir. In a study of US veterans with SARS-CoV-2 infection, different time zero definitions were compared when estimating the drug’s effect on 30-day hospitalization or death. Across all approaches, outcomes were lower in the nirmatrelvir/ritonavir group than in the no-treatment group, but the magnitude of the estimated risk difference varied substantially by design choice, underscoring the importance of aligning eligibility, treatment assignment, and follow-up in pharmacoepidemiologic studies.

Key Publications

• NEWJun Identification of spiropyrrolidinoxindoles as SARS-CoV-2 main protease inhibitor hits from virtual screening. (Journal of computer-aided molecular design, 2026, PMID 42315688): "The current SARS-CoV-2 main protease inhibitor (Mpro), Paxlovid, substantially lowers hospitalization rates but is associated with adverse effects and drug-drug interactions with many medications."
• NEWJun Curcumin-based nanomaterials for dual-target inhibition of SARS-CoV-2 omicron main protease and HMPV RNA polymerase: A computational study. (International journal of biological macromolecules, 2026, PMID 42269888): "Molecular docking analyses revealed that these carbon dots (CDs) exhibited higher binding affinities toward both target proteins compared to curcumin and the corresponding approved drugs, namely nirmatrelvir (for Mpro) and remdesivir (for RdRp)."
• May Design, Synthesis, and Evaluation of Novel Thiazole-Based Peptidomimetic Compounds as Potent SARS-CoV-2 Main Protease Covalent Inhibitors. (ACS infectious diseases, 2026, PMID 42160697): "Compound AD06 (IC50 = 163.3 ± 43.5 nM) exhibited the most potent inhibitory potency against SARS-CoV-2 Mpro, which is comparable to Nirmatrelvir (IC50 = 160.2 ± 15.1 nM) and the lead compound MC12 (167.4 ± 28.6 nM)."
• May Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. (Pulmonary therapy, 2026, PMID 42156669): "This study aimed to describe the demographic and clinical characteristics, treatment patterns, and healthcare resource utilization (HCRU) of adult patients with coronavirus disease 2019 (COVID-19) prescribed nirmatrelvir/ritonavir in the KSA."
• May A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. (Clinical and translational science, 2026, PMID 42012328): "...qualify for treatment with nirmatrelvir/ritonavir."
• Apr Nicotine-Inspired, De Novo-Designed SARS-CoV-2 Main Protease Inhibitors Reveal Unique Chemistry for Covalently Conjugating Both Cysteine and Histidine Residues in the Catalytic Dyad. (Journal of the American Chemical Society, 2026, PMID 41978983): "which contrasts with the extensive hydrogen bond networks formed with peptidomimetic inhibitors such as nirmatrelvir."
• Apr Structure- and Ligand-Based Discovery of Novel 3-Chymotrypsin-Like Protease Nonpeptidomimetic Hits. (ChemMedChem, 2026, PMID 41957532): "While ensitrelvir and nirmatrelvir are approved drugs for treatment, the continuous research and development for new antiviral drugs is necessary to combat the emergence of variants and other related viruses."
• Jun Lopinavir targets Leishmania topoisomerase I and its combination with Ritonavir exhibits enhanced antileishmanial efficacy in clinical isolates of Leishmania donovani. (Acta tropica, 2026, PMID 41946389): "In this study, we demonstrate that the HIV-1 protease inhibitor lopinavir (LPV), particularly in combination with ritonavir (RTV), functions as a selective catalytic inhibitor of LdTopILS."
• Jun Inhibitory potential of Morus alba leaf extract and its phytoconstituent against SARS-CoV-2 main protease: An integrative in silico and in vitro analysis. (Journal of molecular graphics & modelling, 2026, PMID 41875707): "Naringin, nicotiflorin, and cyclomorusin emerged as top hits with binding affinities ranging from -9.8 to -9.6 kcal/mol, compared to the reference drug, i.e., nirmatrelvir (-9.0 kcal/mol)."
• Apr Impact of time zero designation on estimated COVID-19 antiviral effectiveness in observational studies. (American journal of epidemiology, 2026, PMID 41078178): "We compared the impact of different time zero designations on the estimated effectiveness of nirmatrelvir-ritonavir for COVID-19."